SynthesisLung cancer (Amsterdam, Netherlands)2021
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis.
Synthesis in Lung cancer (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Methodological Considerations on COVID-19 Mortality in Cancer Patients: A Systematic Review and Meta-Analysis.JNCI cancer spectrum · 2022Pooled it
- Adverse COVID-19 experiences and physical and psychological outcomes in patients with lung cancer.Palliative & supportive care · 2026Article
- COVID-19 vaccine effectiveness in patients with lung cancer: challenges in the Omicron era.BMC infectious diseases · 2026Article
- [Trend of Death and Years of Life Lost Caused by Lung Cancer in Handan, 2017-2023].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer.ESMO real world data and digital oncology · 2025Article
- A severe acute respiratory coronavirus virus 2 (SARS-CoV-2) nosocomial cluster with inter-facility spread: Lessons learned.Infection control and hospital epidemiology · 2024Article
- COVID-19 or Cancer Stress? Anxiety and Depressive Symptoms in Patients with Advanced Lung Cancer.International journal of behavioral medicine · 2024Article
- Bayesian Inference for High Dimensional Cox Models with Gaussian and Diffused-Gamma Priors: A Case Study of Mortality in COVID-19 Patients Admitted to the ICU.Statistics in biosciences · 2024Article
- Patient Report on the Impact of Coronavirus Disease 2019 and Living With Lung Cancer.JTO clinical and research reports · 2023Article
- SARS-CoV-2 Infection, Hospitalization, and Mortality in Adults With and Without Cancer.JAMA network open · 2023Article
- No Excess of Mortality from Lung Cancer during the COVID-19 Pandemic in an Area at Environmental Risk: Results of an Explorative Analysis.International journal of environmental research and public health · 2023Observational
- Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection.Pathogens (Basel, Switzerland) · 2023Article
- Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis.Translational oncology · 2023Article
- The Impact of COVID-19 Pandemic on Surgical Treatment of Resectable Non-Small Cell Lung Cancer in Greece.Life (Basel, Switzerland) · 2023Article
- Current global research landscape on COVID-19 and cancer: Bibliometric and visualization analysis.World journal of clinical oncology · 2022Article
- Barthel's Index: A Better Predictor for COVID-19 Mortality Than Comorbidities.Tuberculosis and respiratory diseases · 2022Article
- Infection and reinfection with SARS-CoV-2 in cancer patients: A cohort study.Experimental and therapeutic medicine · 2022Article
- International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022Article
- Assessment of Seroconversion after SARS-CoV-2 Vaccination in Patients with Lung Cancer.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGiven that the coronavirus disease 2019 (COVID-19) mainly spreads through the respiratory system and is associated with severe pulmonary complications, lung cancer patients may have worse outcomes than those with other tumors. There is no confirmed evidence about the mortality comparison between COVID-19 patients with lung cancer and other tumors. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate of COVID-19 patients with lung cancer and other tumors. MATERIALS AND
methodsOur study systemically included and reviewed 13 studies on the characteristics of COVID-19 patients with lung cancer published up to November 1, 2020. The primary endpoint was all-cause mortality. We also compared the all-cause mortality rates in China and other regions as a secondary endpoint. The mortality rate was assessed with a fixed-effects model, which was used to derive the pooled mortality and 95 % confidence interval (CI).
resultsThirteen studies from different countries, involving 1,229 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 343 deaths were recorded in this population: 86 for lung cancers and 257 for other tumors. The mortality rate varies from 18 % to 60 % for patients with lung cancer and COVID-19 and 10%-41% for other tumor patients with COVID-19. The overall meta-analysis did not show a significant mortality difference for the lung cancer and other tumor subgroups (OR = 1.47, 95 %CI = 0.98-2.20, p = 0.06, I
conclusionAppropriate and aggressive preventive measures should be implemented to reduce the risk of COVID-19 in patients with cancer and optimally manage those who contract the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.